Background
==========

Cancer is a leading cause of death worldwide. To make things worse, the number of cancer cases and deaths is expected to grow rapidly with increase in populations, age, and adaptation to lifestyle behaviors that increase cancer risk \[[@b1-medscimonit-24-7057]\]. One of the major reasons for variability among individuals is the presence of single-nucleotide polymorphisms (SNPs), which makes individuals more susceptibility to cancer \[[@b2-medscimonit-24-7057]\]. Several explorations related to genome-wide associations have suggested there are many *loci* in the genome that have signs of low tumor susceptibility for common tumors \[[@b3-medscimonit-24-7057]--[@b5-medscimonit-24-7057]\].

MicroRNAs (miRNAs) are a type of single-stranded non-encoded small RNA that can inhibit the transcription of mRNA or promote its degradation at the post-transcription level by binding to the target mRNA 3′ UTR region to regulate gene expression \[[@b6-medscimonit-24-7057],[@b7-medscimonit-24-7057]\]. There is growing evidence that misalignment of miRNA expression affects tumorigenesis based on activation of either tumor suppressor or oncogene \[[@b8-medscimonit-24-7057]--[@b12-medscimonit-24-7057]\]. miRNA gene polymorphism affects tumor susceptibility by destroying miRNA biosynthesis and target gene expression, changing mature miRNA, or by affecting its interaction with target genes \[[@b13-medscimonit-24-7057]--[@b16-medscimonit-24-7057]\]. The relationship between miRNA gene polymorphisms is complicated. For example, in each case, the rs11614913 variant homozygote CC was associated with increased cancer risk. Risk of developing oesophageal cancer in Caucasian males and never-smokers was significantly associated with the rs11614913 variant homozygote TT, the minor allele in this population \[[@b17-medscimonit-24-7057]\]. Rs11614913 is located on the 3′ passenger (3p) strand mature sequence of mir-196a-2, thereby possibly affecting both maturation and the repertoire of target mRNAs with which it interacts. Indeed, previous studies have shown that sequence variations in mature and precursor miRNA sequences affect miRNA biogenesis \[[@b18-medscimonit-24-7057],[@b19-medscimonit-24-7057]\], and levels of mature miR-196a-2 were lower in CC carriers than in TT carriers \[[@b20-medscimonit-24-7057],[@b21-medscimonit-24-7057]\]. Notably, this SNP has also been associated with poor survival in patients with lung cancer.

The miR-34 family members include miR-34a, miR-34b, and miR-34c. miR-34a is encoded by its own transcription, while the miR-34b and miR-34c share a primary transcription (pri-miR-34b/c) \[[@b22-medscimonit-24-7057]\]. In the promoter region of Pri-miR-34b/c, a potentially functional rs4938723 T/C variant may affect the binding of transcription factor Gata-X, thereby changing the expression of pri-miR-34b/c \[[@b23-medscimonit-24-7057]--[@b25-medscimonit-24-7057]\]. The rs4938723 T\>C variant may potentially influence the expression of miR-34b/c via genetic and epigenetic mechanisms, leading to increased or decreased risk of cancer. Previous studies proposed that miR-34b/c is dysregulated in various cancers \[[@b26-medscimonit-24-7057]--[@b28-medscimonit-24-7057]\]. Similar to other kinds of polymorphisms, miR-34b/c rs4938723 polymorphism may influence its own expression, then affect its target genes' expression, finally promoting or inhibiting translation of target proteins to act on several biological functions. For example, Tong (2016) \[[@b29-medscimonit-24-7057]\] reported rs4938723 CC genotype was significantly associated with reduced lymphoblastic leukemia risk, and C-allele may increase the transcription activity of miR-34b/c. However, Chen (2016) \[[@b30-medscimonit-24-7057]\] found that TC+CC genotype was correlated with an increased risk of hepatocellular carcinoma compared to the TT genotype, which disagrees with Tong's results. In addition, Zhu (2015) \[[@b31-medscimonit-24-7057]\] indicated no association between this polymorphism and esophageal squamous cell carcinoma.

A number of meta-analyses with respect to association between this polymorphism and cancer susceptibility have been reported, but with some limitations and false-positive conclusions. Li (2017) \[[@b32-medscimonit-24-7057]\] indicated a rs4938723 polymorphism had a significant relationship with the whole cancer risk. In addition, this polymorphism played an increased risk in hepatocellular carcinoma, but a decreased risk for colorectal, gastric, and esophageal squamous cell cancer. Furthermore, Wang (2014) \[[@b33-medscimonit-24-7057]\] suggested that this polymorphism may be associated with the risk of various types of cancers, including nasopharyngeal cancer, osteosarcoma, and renal cell cancer, especially in Asians. In addition to these 2 meta-analyses, some vital case-control studies were included, and some novel studies were also reported. We considered that it was necessary to re-analyze all case-control studies to assess the association between rs4938723 variant and tumor susceptibility \[[@b22-medscimonit-24-7057],[@b25-medscimonit-24-7057],[@b29-medscimonit-24-7057]--[@b31-medscimonit-24-7057],[@b34-medscimonit-24-7057]--[@b57-medscimonit-24-7057]\].

Material and Methods
====================

Identification strategy
-----------------------

We searched in PubMed, EMbase, Web of Science, CNKI, VIP, and WanFang databases (updated on Sep 10, 2018) using 'polymorphism' or 'variant' or 'single-nucleotide polymorphism (SNP)' or 'mutation', 'cancer' or 'tumor', and 'miR-34b/c' or 'pri-miR-34'. Each publication that assessed the relationship between rs4938723 polymorphism and cancer risk was collected.

Search criterion
----------------

The selection criteria were: (1) evaluation of pri-miR-34b/c rs4938723 and all types of cancer risks, (2) case-control design, and (3) available genotype frequency. Exclusion criteria were: (1) studies with duplicate data (the most recent or complete study with the largest number of cases and controls were included), and (2) studies that have not yet been published.

Data extraction
---------------

The following data were collected: first author, year of publication, race of origin, cancer type by traditional classification, cancer type by our own standard, sample size (cases/controls), each kind of genotype both for case and control groups, study design (HB: hospital-based and PB: population-based), source of control, Hardy-Weinberg equilibrium (HWE) of controls, and genotyping method.

Statistical analysis
--------------------

Odds ratio (OR) with 95% confidence interval (CI) was used to measure the strength of the association between pri-miR-34b/c rs4938723 and cancers. We analyzed this correlation by using 5 different genetic models: C-allele *vs.* T-allele, CC *vs.* TT, CT *vs.* TT, CC+CT *vs.* TT, and CC *vs.* CT+TT. Ethnicity subgroup were categorized as Caucasian, Asian, African, or mixed (if study population was not a pure race). We divided the control group into 4 classes based on source: HB or PB. In the cancer type subgroup, we included hepatocellular carcinoma, leukemia, colorectal cancer, gastric cancer, breast cancer, esophageal cancer, digestive cancer, female specific cancer, and other cancers (if not in the above types).

Heterogeneity assumption was assessed with a chi-square-based *Q*-test. The statistical significance was calculated with the *Z*-test. When P for the heterogeneity test (*Ph*) was more than 0.10, the fixed-effects model was applied; otherwise, the random-effects model was used \[[@b58-medscimonit-24-7057],[@b59-medscimonit-24-7057]\]. The funnel plot asymmetry and publication bias were evaluated by both Egger's test and Begg's test \[[@b60-medscimonit-24-7057],[@b61-medscimonit-24-7057]\]. The departure of frequencies of rs4938723 from expected values under HWE was evaluated in controls using the Pearson chi-square test. All these statistical tests were performed using Stata software (version 11.0; StataCorp LP, College Station, TX).

Results
=======

Study characteristics
---------------------

After reviewing the title, abstract, and full text, we excluded meta-analyses, reviews, case-only studies, and other gene polymorphisms. The flowchart illustrating the search strategy is shown in [Figure 1](#f1-medscimonit-24-7057){ref-type="fig"}. Finally, 29 different papers describing 30 case-control studies \[[@b22-medscimonit-24-7057],[@b25-medscimonit-24-7057],[@b29-medscimonit-24-7057]--[@b31-medscimonit-24-7057],[@b34-medscimonit-24-7057]--[@b57-medscimonit-24-7057]\] evaluating the relationship between rs4938723 polymorphism and cancer were identified. Study characteristics are shown in [Table 1](#t1-medscimonit-24-7057){ref-type="table"}. The HWE in controls was consistent with 0.05, except for 1 study by Chen (2016) \[[@b30-medscimonit-24-7057]\]. To observe a representation of our analysis, we investigated the minor allele frequency from 5 main worldwide populations in the 1000 Genomes Browser: East Asian, 0.305; European, 0.365; African, 0.276; American, 0.219; and South Asian, 0.244 ([Figure 2](#f2-medscimonit-24-7057){ref-type="fig"}). None of the control populations had a history of malignant diseases. Genotyping methods are listed in [Table 1](#t1-medscimonit-24-7057){ref-type="table"}.

Quantitative synthesis
----------------------

### Total analysis

In the total group, no vital relationship was found in all comparisons (e.g., C-allele *vs.* T-allele: OR=1.04; 95% CI=0.97--1.13; *P*~(heterogeneity)~ \<0.001, [Figure 3](#f3-medscimonit-24-7057){ref-type="fig"}). At the same time, if we excluded 1 paper that was not consistent with HWE, a similar association was detected ([Table 2](#t2-medscimonit-24-7057){ref-type="table"}). In addition, no association was detected in subgroup analysis based on ethnicity and source of control ([Table 2](#t2-medscimonit-24-7057){ref-type="table"}).

### Subgroup analysis by cancer type

Detailed results are shown in [Table 2](#t2-medscimonit-24-7057){ref-type="table"}. Statistically significant relationships were observed between pri-miR-34b/c rs4938723 and risk of 4 types of cancers: as a risk factor for hepatocellular carcinoma (e.g., CC *vs.* TT: OR=1.53; 95% CI=1.04--2.23; *P*~(heterogeneity)~\<0.001, [Figure 4](#f4-medscimonit-24-7057){ref-type="fig"}), but as a protective factor for leukemia (e.g., CC *vs.* TT: OR=0.52; 95% CI=0.34--0.79; *P*~(heterogeneity)~=0.411 for heterogeneity, [Figure 5](#f5-medscimonit-24-7057){ref-type="fig"}), colorectal cancer (CC *vs.* CT+TT: OR=0.67; 95% CI=0.48--0.93; *P*~(heterogeneity)~=0.519 for heterogeneity, [Figure 6](#f6-medscimonit-24-7057){ref-type="fig"}), and esophageal cancer (CC *vs.* CT+TT: OR=0.76; 95% CI=0.63--0.91; *P*~(heterogeneity)~=0.251 for heterogeneity, [Figure 6](#f6-medscimonit-24-7057){ref-type="fig"}) ([Table 2](#t2-medscimonit-24-7057){ref-type="table"}).

### Subgroup analysis by age and other kinds of analysis

Interestingly, in the age subgroup, decreased associations were found both in \<62 (OR=0.70; 95% CI=0.50--0.98; *P*~(heterogeneity)~=0.654 for heterogeneity) and ≥62 groups (OR=0.68; 95% CI=0.50--0.93; *P*~(heterogeneity)~=0.942 for heterogeneity) ([Figure 7](#f7-medscimonit-24-7057){ref-type="fig"}, [Table 2](#t2-medscimonit-24-7057){ref-type="table"}). No association was detected in subgroups based on sex, smoking status, and drinking ([Table 2](#t2-medscimonit-24-7057){ref-type="table"}).

### Relationships between rs4938723 polymorphism and prognosis of cancer

To our regret, no association between this polymorphism and cancer prognosis in 2 models (localized and advanced) (CC+CT *vs.* TT: OR=1.15; 95% CI=0.91--1.46; *P*~(heterogeneity)~=0.735 for heterogeneity, *P*=0.237 for *Z*-test) was found ([Table 3](#t3-medscimonit-24-7057){ref-type="table"}).

### Publication bias diagnosis and sensitivity analysis

Both Begg's funnel plot and Egger's test were applied to assess the publication bias. No publication bias was detected \[for example (C-allele *vs.* T-allele) (*z*=0.27, *P*=0.789 for Begg's test; *t*=0.24, *P*=0.809 for Egger's test, [Figures 8](#f8-medscimonit-24-7057){ref-type="fig"}, [9](#f9-medscimonit-24-7057){ref-type="fig"})\] ([Table 4](#t4-medscimonit-24-7057){ref-type="table"}). Despite the above results, each study reflected the influence of the individual dataset on the pooled OR, and observed that the corresponding pooled OR was not significantly altered, indicating that our results were statistically robust (for example: allelic contrast, [Figure 10](#f10-medscimonit-24-7057){ref-type="fig"}).

Discussion
==========

mir-34b/c gene is part of the p53 pathway and enhances its tumor suppressor activities \[[@b62-medscimonit-24-7057], [@b63-medscimonit-24-7057]\]; it transcribes microRNA-34 b and c, which inhibit p53 antagonists \[[@b64-medscimonit-24-7057]\], cyclin-dependent kinases, and pro-apoptotic proteins \[[@b65-medscimonit-24-7057]\]. The deregulation of miR-34b/c was observed in several carcinoma cells, and cell proliferation, apoptosis, migration, and invasion were involved. Recently, a SNP located at the promoter region of mir-34b/c gene (rs4938723T/C) was identified, and its role in tumorigenesis has been widely investigated, as it can alter miR-34b/c transcription levels, because it can affect GATA-X binding. Presence of C in this location leads to binding to the GATA-X \[[@b33-medscimonit-24-7057]\].

Our meta-analysis explored the association between pri-miR-34b/c rs4938723 and overall cancer susceptibility, involving 13 950 cancer cases and 16 071 controls. The main results of our analysis are that this polymorphism has different associations with different types of cancer: increased association for hepatocellular carcinoma, but decreased association for leukemia, colorectal, and esophageal cancer. The following reasons may explain these results. First, differences in the distribution of various cancers between cases and controls might be a source of variability during pooling. Second, rs4938723 polymorphism might carry out different functions in different types of cancers. Third, because cancer is a multi-factorial disease caused by the complex interactions between many genetic and environmental factors, there is no single gene or environmental factor that has a significant effect on cancer susceptibility \[[@b66-medscimonit-24-7057]\]. The present study differs from previous meta-analyses in that we included some environmental and clinical factors, such as sex, smoking status, age, drinking, and prognosis of cancer. Of note, a positive association was found in the age subgroup. Our results were also different from those of previous meta-analyses \[[@b32-medscimonit-24-7057],[@b33-medscimonit-24-7057]\] because previously there had been no association between this polymorphism and the whole cancer risk, as well as no association for Asians and gastric cancer risk. This was because the relatively small samples in previous analysis resulted in false-positive results. So, it made sense to recombine all studies to gain a comprehensive and credible conclusion, and to correct error at the same time.

Some limitations should be considered. First, sample sizes varied widely in the different studies (range of the number of cases/controls: 110/120 to 1109/1275), which may increase the publication bias. Second, there were only 2 case-control studies regarding leukemia, colorectal, and gastric cancer; future studies should also focus on these types of cancers. Third, few studies used mixed, Caucasian, or African populations; future studies should also focus on these races. Fourth, additional studies are needed to address the effects of race and sample size on the predicted associations, and more attention must be placed on gene-gene and gene-environment interactions. Fifth, other environmental factors, such as dietary factors and infectious agents, increase the load of carcinogenic substances humans are exposed to.

Conclusions
===========

Our present analysis found novel evidence that the pri-miR-34b/c rs4938723 polymorphism had 2-tier effects on the risk of different types of cancers: rs493723 polymorphism was associated increased risk of hepatocellular carcinoma and decreased risk of leukemia, colorectal and esophageal cancer. Further studies with larger samples are needed to evaluate associations between rs4938723 polymorphism and each type of cancer.
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![Flowchart illustrating the search strategy used to identify association studies for pri-miR-34b/c rs4938723 polymorphism and whole cancer risk.](medscimonit-24-7057-g001){#f1-medscimonit-24-7057}

![The MAF of minor allele (mutant-allele) for pri-miR-34b/c rs4938723 polymorphism from the 1000 Genomes online database and present analysis. EAS -- East Asian; EUR -- European; AFR -- African; AMR -- American; SAS -- South Asian.](medscimonit-24-7057-g002){#f2-medscimonit-24-7057}

![Forest plot of cancer risk associated with pri-miR-34b/c rs4938723 polymorphism (C-allele *vs.* T-allele) in the whole. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](medscimonit-24-7057-g003){#f3-medscimonit-24-7057}

![Forest plot of hepatocellular carcinoma associated with pri-miR-34b/c rs4938723 polymorphism (CC *vs.* TT). The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](medscimonit-24-7057-g004){#f4-medscimonit-24-7057}

![Forest plot of leukemia risk associated with pri-miR-34b/c rs4938723 polymorphism (CC *vs.* TT). The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](medscimonit-24-7057-g005){#f5-medscimonit-24-7057}

![Forest plot of colorectal and esophageal cancer risk associated with pri-miR-34b/c rs4938723 polymorphism (CC *vs.* CT+TT). The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](medscimonit-24-7057-g006){#f6-medscimonit-24-7057}

![Forest plot of cancer risk associated with pri-miR-34b/c rs4938723 polymorphism (CC *vs.* CT+TT) in the age subgroup. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](medscimonit-24-7057-g007){#f7-medscimonit-24-7057}

![Begg's funnel plot for publication bias test (C-allele *vs.* T-allele). Each point represents a separate study for the indicated association. Log \[OR\], natural logarithm of OR. Horizontal line, mean effect size.](medscimonit-24-7057-g008){#f8-medscimonit-24-7057}

![Egger's publication bias plot (C-allele *vs.* T-allele).](medscimonit-24-7057-g009){#f9-medscimonit-24-7057}

![Sensitivity analysis between pri-miR-34b/c rs4938723 polymorphism and TB risk (C-allele *vs.* T-allele).](medscimonit-24-7057-g010){#f10-medscimonit-24-7057}

###### 

Basic information for included studies of the association between pri-miR-34b/c rs4938723 polymorphism site and whole cancer susceptibility.

  First author (year) \[ref no.\]                  Origin        Ethnicity   Design   Case   Control   Case   Control   Method   Cancer type (1)   Cancer type (2)                                                                                           
  ------------------------------------------------ ------------- ----------- -------- ------ --------- ------ --------- -------- ----------------- ----------------- ----- ------ ---------------------------------------------- --------------------------- ------------------------
  Bensen (2013) \[[@b34-medscimonit-24-7057]\]     USA           African     PB       742    658       63     317       362      58                257               343   0.32   Illumina                                       Breast cancer               Female specific cancer
  Sanaei (2016) \[[@b47-medscimonit-24-7057]\]     Canada        Caucasian   PB       263    221       23     115       125      15                106               100   0.06   PCR-RFLP                                       Breast cancer               Female specific cancer
  bensen (2013) \[[@b34-medscimonit-24-7057]\]     USA           Caucasian   PB       1203   1088      144    563       496      155               503               430   0.68   Illumina                                       Breast cancer               Female specific cancer
  gao (2013) \[[@b38-medscimonit-24-7057]\]        China         Asian       HB       347    488       28     144       175      62                210               216   0.33   PCR-RFLP                                       Colorectal cancer           Digestive cancer
  Oh (2014) \[[@b45-medscimonit-24-7057]\]         South Korea   Asian       HB       545    428       40     233       272      41                171               216   0.40   PCR-RFLP                                       Colorectal cancer           Digestive cancer
  yin (2013) \[[@b52-medscimonit-24-7057]\]        China         Asian       HB       600    673       45     278       277      73                290               310   0.67   PCR-LDR                                        Esophageal cancer           Digestive cancer
  zhu (2015) \[[@b31-medscimonit-24-7057]\]        China         Asian       PB       237    274       25     99        113      30                122               122   0.95   MALDI-TOF-MS                                   Esophageal cancer           Digestive cancer
  zhang (2) (2014)\[[@b55-medscimonit-24-7057]\]   China         Asian       PB       1109   1275      84     536       489      133               573               569   0.52   SNaPshot Multiplex System                      Esophageal cancer           Digestive cancer
  you (2011) \[[@b53-medscimonit-24-7057]\]        China         Asian       PB       251    189       28     103       120      15                86                88    0.34   MALDI-TOF-MS                                   Esophageal cancer           Digestive cancer
  yang (2014) \[[@b51-medscimonit-24-7057]\]       China         Asian       HB       419    402       40     186       193      62                184               156   0.52   PCR-RFLP                                       Gastric cancer              Digestive cancer
  pan (2015) \[[@b46-medscimonit-24-7057]\]        China         Asian       HB       197    289       19     76        102      31                137               121   0.39   PCR-RFLP                                       Gastric cancer              Digestive cancer
  son (2013) \[[@b49-medscimonit-24-7057]\]        South Korea   Asian       HB       157    201       13     75        69       17                74                110   0.37   PCR-RFLP                                       Hepato-cellular carcinoma   Digestive cancer
  han (2013) \[[@b39-medscimonit-24-7057]\]        China         Asian       HB       1013   999       118    444       451      119               424               456   0.18   fluorescent-probe real-time quantitative PCR   Hepato-cellular carcinoma   Digestive cancer
  xu (2011) \[[@b25-medscimonit-24-7057]\]         China         Asian       PB       502    549       62     236       204      54                229               266   0.65   PCR-RFLP                                       Hepato-cellular carcinoma   Digestive cancer
  chen (2016) \[[@b30-medscimonit-24-7057]\]       China         Asian       HB       286    572       38     146       102      33                267               272   0.00   PCR-RFLP                                       Hepato-cellular carcinoma   Digestive cancer
  tong (2016) \[[@b29-medscimonit-24-7057]\]       China         Asian       HB       570    673       35     281       254      76                296               301   0.80   TaqMan                                         Leukemia                    Other cancers
  hashemi (2017)\[[@b41-medscimonit-24-7057]\]     Iran          Caucasian   PB       110    120       2      31        77       6                 52                62    0.24   PCR-RFLP                                       Leukemia                    Other cancers
  yuan (2016) \[[@b54-medscimonit-24-7057]\]       China         Asian       HB       328    568       36     175       117      68                258               242   0.95   PCR-RFLP                                       Cervical cancer             Female specific cancer
  li (2013) \[[@b43-medscimonit-24-7057]\]         China         Asian       PB       217    360       31     104       82       37                155               168   0.89   PCR-RFLP                                       Nasoph-aryngeal carcinoma   Other cancers
  tian (2014) \[[@b50-medscimonit-24-7057]\]       China         Asian       PB       133    133       30     62        41       18                53                62    0.22   TaqMan                                         Osteo-sarcoma               Other cancers
  hashemi (2016)\[[@b40-medscimonit-24-7057]\]     Iran          Caucasian   HB       152    152       10     56        85       5                 38                109   0.46   PCR-RFLP                                       Prostate cancer             Other cancers
  Zhang (1) (2014)\[[@b22-medscimonit-24-7057]\]   China         Asian       HB       710    760       84     324       302      64                344               352   0.11   TaqMan                                         Renal cell cancer           Other cancers
  carvalho (2017)\[[@b36-medscimonit-24-7057]\]    Brazil        Mixed       PB       130    105       14     64        52       16                44                45    0.34   sequencing                                     Retino-blastoma             Other cancers
  liu (2017) \[[@b44-medscimonit-24-7057]\]        China         Asian       HB       164    305       26     80        58       22                141               142   0.10   PCR-RFLP                                       Hepato-cellular carcinoma   Digestive cancer
  Chen (2015) \[[@b37-medscimonit-24-7057]\]       China         Asian       HB       784    1006      111    402       271      99                451               456   0.41   PCR-RFLP                                       Thyroid carcinoma           Other cancers
  Bulibu (2018) \[[@b35-medscimonit-24-7057]\]     China         Asian       PB       175    186       37     74        64       53                81                52    0.08   PCR-DHPLC                                      Esophageal cancer           Digestive cancer
  Wu (2017) \[[@b56-medscimonit-24-7057]\]         China         Asian       PB       893    990       92     396       405      84                430               476   0.34   MassARRAY                                      Gastric cancer              Digestive cancer
  Singh (2017) \[[@b48-medscimonit-24-7057]\]      China         Asian       HB       324    598       44     148       132      66                262               270   0.84   PCR-LDR                                        Gastric cancer              Digestive cancer
  He (2018) \[[@b42-medscimonit-24-7057]\]         China         Asian       HB       377    810       49     107       221      75                358               377   0.45   TaqMan                                         Neuro-blastoma              Other cancers
  Pu (2012) \[[@b57-medscimonit-24-7057]\]         China         Asian       HB       1013   999       118    444       451      119               424               456   0.18   Fluorescent Probe-Real-time Quantitative PCR   Hepato-cellular carcinoma   Digestive cancer

HWE -- Hardy-Weinberg equilibrium; HB -- hospital-based; PB -- population-based; PCR-FLIP -- polymerase chain reaction and restrictive fragment length polymorphism; MALDI-TOF-MS -- matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; DHPLC -- denaturing high performance liquid chromatography; LDR -- ligation detection reaction.

###### 

Total and stratified subgroup analysis for pri-miR-34b/c rs4938723 polymorphism site and cancer susceptibility.

  Variables                  N    Case/control   C-allele *vs.* T-allele   CT *vs.* TT   CC *vs.* TT         CC+CT *vs.* TT   CC *vs.* CT+TT                                                                  
  -------------------------- ---- -------------- ------------------------- ------------- ------------------- ---------------- ------------------- --------- ------------------- --------- ------------------- ---------
  Total                      30   13950/ 16071   1.04 (0.97--1.13)         \<0.001       1.07 (0.98--1.17)   \<0.001          1.07 (0.91--1.27)   \<0.001   1.07 (0.97--1.18)   \<0.001   1.03 (0.89--1.19)   \<0.001
  HWE                        29   13664/ 15499   1.03 (0.95--1.12)         \<0.001       1.09 (0.99--1.20)   \<0.001          0.99 (0.83--1.19)   \<0.001   1.07 (0.97--1.19)   \<0.001   0.94 (0.81--1.10)   \<0.001
  **Ethnicity**                                                                                                                                                                                               
  Asian                      24   10351/ 13727   1.06 (0.97--1.15)         \<0.001       1.08 (0.97--1.19)   \<0.001          1.10 (0.91--1.32)   \<0.001   1.08 (0.97--1.20)   \<0.001   1.05 (0.89--1.24)   \<0.001
  Caucasian                  4    1727/ 1581     0.97 (0.69--1.35)         0.001         0.95 (0.64--1.40)   0.004            1.00 (0.56--1.78)   0.076     0.95 (0.63--1.43)   0.001     0.88 (0.71--1.10)   0.151
  African                    1    742/ 658       --                                      --                                   --                            --                            --                  
  Mixed                      1    130/ 105       --                                      --                                   --                            --                            --                  
  China                      22   10649/ 13098   1.05 (0.96--1.15)         \<0.001       1.06 (0.96--1.18)   \<0.001          1.11 (0.91--1.36)   \<0.001   1.07 (0.96--1.20)   \<0.001   1.07 (0.90--1.27)   \<0.001
  Non-China                  8    3301/ 2973     1.02 (0.87--1.18)         0.004         1.09 (0.89--1.33)   0.006            0.90 (0.75--1.07)   0.286     1.06 (0.87--1.30    )0.002    0.87 (0.74--1.03)   0.479
  **Source of control**                                                                                                                                                                                       
  HB                         17   7985/ 9923     1.07 (0.95--1.20)         \<0.001       1.09 (0.94--1.27)   \<0.001          1.10 (0.85--1.43)   \<0.001   1.10 (0.95--1.28)   \<0.001   1.05 (0.84--1.32)   \<0.001
  PB                         13   5965/ 6149     1.02 (0.92--1.14)         \<0.001       1.05 (0.93--1.18)   0.022            1.05 (0.84--1.31)   0.002     1.04 (0.91--1.19)   0.002     1.01 (0.84--1.21)   0.018
  **Cancer type**                                                                                                                                                                                             
  Hepatocellular carcinoma   6    5421/ 6411     1.23 (1.06--1.44)         0.001         1.19 (1.07--1.32)   0.156            1.53 (1.04--2.23)   \<0.001   1.29 (1.08--1.53)   0.019     1.34 (0.97--1.86)   0.002
  Leukemia                   2    680/ 793       0.71 (0.42--1.20)         0.031         0.76 (0.33--1.75)   0.006            0.52 (0.34--0.79)   0.411     0.71 (0.33--1.52)   0.009     0.50 (0.33--0.75)   0.657
  Colorectal cancer          2    892/ 916       0.87 (0.75--1.01)         0.154         0.97 (0.79--1.17)   0.222            0.66 (0.47--0.92)   0.342     0.90 (0.75--1.09)   0.157     0.67 (0.48--0.93)   0.519
  Gastric cancer             4    1833/ 2279     0.94 (0.75--1.18)         0.001         0.93 (0.75--1.17)   0.381            0.92 (0.58--1.47)   0.400     0.92 (0.71--1.20)   0.007     0.96 (0.66--1.47)   0.022
  Breast cancer              3    2208/ 1967     0.97 (0.89--1.07)         0.304         1.02 (0.90--1.16)   0.289            0.90 (0.73--1.10)   0.386     1.00 (0.88--1.13)   0.287     0.89 (0.73--1.08)   0.387
  Esophageal cancer          5    2372/ 2597     0.93 (0.85--1.01)         0.475         1.02 (0.90--1.14)   0.049            0.76 (0.62--0.92)   0.346     0.97 (0.86--1.08)   0.500     0.76 (0.63--0.91)   0.251
  Digestive cancer           17   8232/ 9417     1.02 (0.92--1.13)         \<0.001       1.05 (0.96--1.16)   0.019            1.02 (0.80--1.29)   \<0.001   1.04 (0.93--1.17)   \<0.001   0.99 (0.81--1.22)   \<0.001
  Female specific cancer     4    2535/ 2536     1.00 (0.92--1.09)         0.228         1.09 (0.91--1.31)   0.098            0.93 (0.77--1.12)   0.473     1.05 (0.93--1.17)   0.109     0.89 (0.75--1.07)   0.593
  Other cancers              8    2830/ 3894     1.22 (1.04--1.24)         \<0.001       1.24 (0.92--1.17)   \<0.001          1.50 (1.26--1.77)   0.102     1.29 (0.99--1.70)   \<0.001   1.37 (1.17--1.60)   0.249
  **Sex**                                                                                                                                                                                                     
  Male                       6    2674/ 3099     --                                      --                                   --                            0.90 (0.53--1.52)   \<0.001   0.92 (0.55--1.55)   0.007
  female                     6    1042/ 1369     --                                      --                                   --                            0.75 (0.48--1.17)   0.085     0.80 (0.56--1.14)   0.234
  **Somking status**                                                                                                                                                                                          
  Ever                       5    1669/ 1488     --                                      --                                   --                            1.04 (0.53--2.02)   0.046     0.92 (0.47--1.79)   0.006
  Never                      5    1670/ 2170     --                                      --                                   --                            1.03 (0.56--1.89)   0.014     0.85 (0.65--1.11)   0.141
  **Drinking**                                                                                                                                                                                                
  Ever                       3    968/ 778       --                                      --                                   --                            --                            0.94 (0.55--1.62)   0.062
  Never                      3    1451/ 1930     --                                      --                                   --                            --                            0.81 (0.48--1.37)   0.013
  Age                                                                                                                                                                                                         
  \<62                       2    814/ 938       --                                      --                                   --                            --                            0.70 (0.50--0.98)   0.654
  ≥62                        2    895/ 1010      --                                      --                                   --                            --                            0.68 (0.50--0.93)   0.942

*P*~h~ -- value of *Q*-test for heterogeneity test.

###### 

Relationship between pri-miR-34b/c rs4938723 polymorphism and cancer prognosis.

  Genotype   Localised   Advanced   OR (95%CI)          *P*~h~   *P*
  ---------- ----------- ---------- ------------------- -------- -------
  CC+CT      446         261                                     
  TT         317         242        1.15 (0.91--1.46)   0.735    0.237
  CC         156         83                                      
  CT+TT      947         605        1.71 (0.79--3.71)   0.001    0.174

*P*~h~ -- value of *Q*-test for heterogeneity test

###### 

Publication bias tests (Begg's funnel plot and Egger's test for publication bias test) for pri-miR-34b/c rs4938723 polymorphism.

  Genetic type            Egger's test   Begg's test                                           
  ----------------------- -------------- ------------- ------ ------- ----------------- ------ -------
  C-allele vs. T-allele   0.282          1.154         0.24   0.809   (−2.082, 2.646)   0.27   0.789
  CT *vs.* TT             0.607          0.927         0.65   0.519   (−1.311, 2.526)   0.44   0.657
  CC *vs.* TT             0.293          0.509         0.58   0.57    (−0.760, 1.347)   0.68   0.498
  CC+TC *vs.* TT          0.651          0.972         0.67   0.51    (−1.360, 2.661)   0.49   0.624
  CC *vs.* TC+TT          0.281          0.534         0.53   0.604   (−0.825, 1.387)   0.54   0.591
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